Evolus, Inc. SEC Filings

Evolus, Inc. director and officer David Moatazedi reported a mix of equity compensation vesting and related share sales. On March 16, 2026, 67,489 performance restricted stock units (PSUs) vested and settled into the same number of common shares after achievement of 100% of target performance on a 134,977-PSU award granted on February 7, 2024. The remaining 67,488 PSUs from that grant are scheduled to vest on February 7, 2027, subject to continued service.

On March 17, 2026, he sold 116,720 shares of common stock in open-market transactions at a weighted average price of $4.8883 per share. According to the disclosure, these sales were made under a Rule 10b5-1 trading plan and were required to cover tax withholding obligations tied to the vesting and settlement of multiple PSU and restricted stock unit awards. Following these transactions, Moatazedi directly held 618,369 shares of Evolus common stock.

Evolus, Inc. executive Rui Avelar reported a routine mix of equity vesting and tax-related share sales. On March 16, 2026, 8,804 performance restricted stock units vested and converted into common shares at a conversion price of $0.0000 per share, with 8,802 PSUs scheduled to vest on February 7, 2027 subject to continued service. On March 17, 2026, he sold 29,996 common shares at a weighted average price of $4.8883 per share under a Rule 10b5-1 trading plan to cover tax withholding obligations tied to multiple PSU and restricted stock unit awards. Following these transactions, he directly holds 430,542 shares of Evolus common stock.

Evolus, Inc. reported a technical change to its board structure. After a prior director departure created an imbalance among its three director classes, the board reclassified director Vikram Malik from Class III to Class II on March 13, 2026 to restore an even distribution.

To accomplish this, Malik briefly resigned as a Class III director and was immediately reappointed as a Class II director, with his board service remaining continuous. He continues as Chairman of the Board and a member of the Compensation Committee, with no new equity awards and existing grants vesting under their original terms.

Evolus, Inc. is a global performance beauty company focused on cash-pay medical aesthetics, selling the neurotoxin Jeuveau and a line of injectable HA gels branded Evolysse. Jeuveau is approved for frown lines in multiple markets, while Evolysse Form and Smooth were approved in the United States in 2025 for wrinkles and folds.

The company targets growth in large neurotoxin and dermal filler segments but continues to post losses, with a $51.6 million net loss in 2025 and an accumulated deficit of $661.0 million. Evolus depends heavily on manufacturing and licensing partners Daewoong and Symatese, and pays Medytox royalties on Jeuveau sales, which reduces profitability.

Evolus highlights competitive pressures from larger players, regulatory and trade risks, reliance on consumer discretionary spending, and the need for additional financing if assumptions prove incorrect. As of the last reported figures, the company had an approximate market value of $560.4 million and 334 employees across the United States, Canada, Europe and Australia.

Evolus, Inc. entered a new senior secured, asset-based revolving credit facility of up to $30.0 million with Eclipse Business Capital, maturing on March 3, 2029, with an uncommitted $10.0 million accordion and a $10.0 million minimum utilization requirement.

Borrowings price at adjusted term SOFR (floor 2.0%) plus a 4.25% margin, with closing fees of 1.0% and prepayment fees starting at 3.0% and stepping down over two years. The facility is secured by substantially all company assets and includes covenants on minimum excess availability and capital expenditures.

For 2025, Evolus generated total net revenue of $297.2 million, up 12%, with Q4 revenue of $90.3 million and Q4 GAAP operating income of $4.2 million. Full-year GAAP loss from operations was $32.7 million and net loss was $51.6 million, while non-GAAP operating loss was $9.4 million. The company ended 2025 with cash of $53.8 million and total liabilities of $249.0 million, resulting in a stockholders’ deficit of $23.1 million.

Evolus projects 2026 revenue of $327–$337 million (growth of 10–13%), adjusted gross margin of 65.5–67.0% and non-GAAP operating expenses of $210–$216 million, aiming for a low- to mid-single digit Adjusted EBITDA margin in 2026 and 13–15% Adjusted EBITDA margins on $450–$500 million revenue by 2028.

Parschauer Karah Herdman reported acquisition or exercise transactions in this Form 4 filing.

Evolus, Inc. director Karah Herdman Parschauer reported an equity compensation grant in the form of restricted stock units (RSUs). The filing shows an award of 45,559 shares of common stock at a price of $0.00 per share, bringing her directly owned total to 77,742 shares.

According to the disclosure, these 45,559 RSUs each represent a contingent right to receive one share of Evolus common stock. The RSUs are scheduled to vest in full on the one year anniversary of February 17, 2026, if she remains in continuous service through the vesting date, with potential accelerated vesting in certain change-of-control and other specified events.

Stewart Brady reported acquisition or exercise transactions in this Form 4 filing.

Evolus, Inc. director Stewart Brady reported receiving a grant of 45,559 shares of common stock in the form of restricted stock units (RSUs). The award was priced at $0.00 per share, increasing his directly held common stock (including RSUs) to 134,188 shares after the transaction.

Each RSU represents a contingent right to receive one Evolus common share. The RSUs will vest in full on the one-year anniversary of February 17, 2026, if Brady remains in continuous service through the vesting date, with potential accelerated vesting upon certain changes of control of the company.

Evolus, Inc. Chief Financial Officer Tatjana Mitchell reported equity awards on Form 4. She acquired 121,489 performance restricted stock units, 177,471 stock options, and 121,489 shares of common stock at a grant price of $0.00 per share, all held directly.

The restricted stock units vest in four equal annual installments starting on February 17, 2026, with potential acceleration upon certain terminations or a change in control. The performance-based units can deliver up to 200% of the granted amount based on financial metrics and relative total shareholder return over a three-year period ending December 31, 2028. The stock options also vest in four equal annual installments beginning on February 17, 2026, subject to continued service and similar acceleration conditions.

White Albert G III reported acquisition or exercise transactions in this Form 4 filing.

Evolus, Inc. director Albert G. White III received an equity award of 45,559 shares of common stock in the form of restricted stock units (RSUs) on February 17, 2026. The award was granted at no cash cost per share and is a stock-based compensation grant, not an open-market purchase.

Each RSU represents a contingent right to receive one Evolus common share and will vest in full on “the one year anniversary of February 17, 2026,” if he remains in continuous service, with potential accelerated vesting upon certain changes of control. Following this grant, his reported direct holdings total 95,937 shares of common stock.